Brodalumab Drugbank ID : DB11776 Molecular Weight (Daltons) :144,000 Description : Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Indication : Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Pharmacodynamics : Increase in the level of IL-17 due to blocking of its receptors. Mechanism of action : Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Volume of distribution : 4.62 L Clearance : 0.223 L/day.

Categories : Antineoplastic and Immunomodulating Agents Targets : Interleukin 17 receptor A Brands : Siliq Formulation : Each SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8. Form : sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution Route of administration : Subcutaneous

Dosage : The recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks. Contraindication : SILIQ is contraindicated in patients with Crohn’s disease because SILIQ may cause worsening of disease Side effects : Suicidal Ideation and Behavior, Infection and Crohn’s Disease

Useful links http://www.rxlist.com/siliq-drug.htm